SWK — Q2 2020 Earnings Presentation
32 slides from SWK's earnings presentation, Aug 17, 2020
Slide 1: Q2 2020 Shareholder Presentation
Collaborative Approach to Life Science Financing Q2 2020 Shareholder Presentation August 14, 2020 1
Slide 2: Forward-looking and Cautionary Statements
Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities
Slide 3: SWK Holdings - Overview
SWK Holdings - Overview Custom financing solutions for commercial-stage healthcare companies and royalty owners • SWK targets $5mm to $20mm financings, a market niche that is largely ignored by larger market participants and generates attractive full-cycle returns Underserved, High- • Business focus
Slide 4: SWK Holdings - Segments
SWK Holdings - Segments SWK operates through two segments: Life Science Specialty Finance and Enteris BioPharma Centered on SWK’s core focus on monetizing revenue streams and intellectual property LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Peptelligence® dosing te
Slide 5: Life Science Finance Opportunity
Life Science Finance Opportunity Achieve high current yield from investment in non-correlated assets Access to capital is challenging for small/midsized life science cos - Few participants exist for sub-$20mm life science financings Life science products are highly portable - Approved & marketed pro
Slide 6: Value Creation Strategy
Value Creation Strategy • SWK has established reputation as a go-to capital provider for this Deploy balance sheet underserved market capital into secured • Majority of financings structured with warrants or other upside financing portfolio features to enhance return profile Selectively consider non
Slide 7: Book Value Components
Book Value Components • Excludes value of deferred tax asset, net Enteris intangibles and Tangible Finance Book goodwill*, and Enteris PP&E Value / Share = $15.05 • SWK’s targets 10%+ CAGR of tangible finance book value / share • In August 2019, SWK paid $21.5 million upfront to acquire Enteris • Th
Slide 8: Corporate Milestones
Corporate Milestones 2020 2019 ✓ Uplisted to Nasdaq and 2018 ✓ 17th partner exit added to realized, 2017 ✓ Secured $20mm bringing the Russell 2000 credit facility Index ✓ Holmdel sold – weighted avg. with State Bank 2016 3.5x CoC return IRR on all exits ✓ Dr. Rajiv Khosla to 20% hired as Enteris ✓ T
Slide 9: Finance Segment Portfolio Overview: 2Q20
Finance Segment Portfolio Overview: 2Q20 Portfolio Composition 1% Financing • Yielding Assets:* $178.7mm 11% Segment • Total Investment Assets:** $182.3mm Portfolio Value • Actively Financed Entities: 23 • Avg. GAAP Balance per Entity: $7.8mm Metrics • Non-Accrual Balance: $16.2mm • Total Unfunded C
Slide 10: Financial Snapshot
Financial Snapshot Total Yielding Assets* SWK Stockholders' Equity ($ in millions; at end of period) ($ in millions, except per share data) $200 $250 $20.00 $236.5 $232.1 $178.7 $175.1 $225 $17.50 $175 $167.1 $213.1 $208.0 $204.3 $153.9 $200 $15.00 $150 $132.2 $175 $12.50 $125 $150 $10.00 2016 2017
Slide 11: Financing Strategy: Effective Yields
Financing Strategy SWK Targets Low-to-Mid Teens Effective Yields 2Q20 Finance Segment Effective Yield was 13.2% Yielding Portfolio and Weighted Effective Yield ($ in millions; at end of period) $200.0 17.5% $175.0 $150.0 15.0% $125.0 12.5% $100.0 $75.0 10.0% $50.0 7.5% $25.0 $- 5.0% Yielding Portfol
Slide 12: Current Structured Credit Portfolio
Current Structured Credit Portfolio Eton Pharmaceuticals Misonix 11.14.19 9.27.19 $15 million – Structured $30 million – Structured Credit Credit CONFIDENTIAL 12
Slide 13: Current Royalty Portfolio
Current Royalty Portfolio CONFIDENTIAL 13
Slide 14: Portfolio Realizations
Portfolio Realizations As of June 30, 2020 SWK has exited 17 financings for a total 1.2x CoC return and 20% weighted average IRR ̶ 14 resulted in positive realizations with a cumulative 1.4x CoC and weighted average 32% IRR ̶ SynCardia position was sold to distressed private equity firm with SWK r
Slide 15: Portfolio Realizations to Strategic Buyers
Portfolio Realizations to Strategic Buyers Ten realizations to strategic buyers demonstrated a median 30% LTV of SWK’s original loan value Seven of the ten businesses were not profitable at time of sale, validating SWK’s revenue and IP-based underwriting methodology $ in mm Target Transaction SW
Slide 16: Sourcing
Sourcing SWK has a well-developed and diversified sourcing network SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers SWK typically faces limited competition due to proprietary sourcing network and focus on sub-$20mm financings From 2017
Slide 17: Financing Structures
Financing Structures • Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities Structured Debt • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercializa
Slide 18: Value Proposition to Partners
Value Proposition to Partners Asset base and nimble structure position SWK to serve the sub-$20mm financing market Smaller companies often don’t have financial profile to qualify for traditional financing sources Companies in this niche often have few options outside of a dilutive equity raise
Slide 19: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth from expanded distribution, not price hikes OPPORTUNITY SOLUTION • Opiant is a publicly traded drug development co
Slide 20: Historical Financing: Galil Medical
Historical Financing: Galil Medical Galil is a privately-held medical device company that delivers innovative cryotherapy solutions for tumor ablation OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue • In December 2014, SWK provided a $12.5mm senior growth, but was not y
Slide 21: Enteris BioPharma Acquisition – A Transformational Opportunity
Enteris BioPharma Acquisition – A Transformational Opportunity • Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on Synergistic & Value life science products in a mix of structures Enhancing • Enteris offers opportunity to create wholly-owned p
Slide 22: Enteris Corporate Overview
Enteris Corporate Overview Proven Technology, Late-Stage Commercial Partnerships, and Internal Pipeline Drug Delivery Technology Commercial Platform • Peptelligence technology allows for oral delivery of drugs that are • Generates revenue three ways: typically injected, including peptides and BCS cl
Slide 23: Enteris Transaction Overview
Enteris Transaction Overview $21.5mm paid upfront to acquire 100% of Enteris’ capital stock Proceeds from Cara Therapeutics licensing agreement, which includes milestone payments and low-single digit royalties on sales of Oral Korsuva™: ̶ Seller will receive 100% of $8.0mm upfront payment ̶ SWK
Slide 24: Leadership Team
Leadership Team Winston Black Charles Jacobsen Jody Staggs Yvette Heinrichson Dr. Rajiv Kholsa Chief Executive Officer Chief Financial Officer Managing Director Chief Accounting Officer Enteris subsidiary CEO • Appointed CEO in • Appointed CFO in • Joined in 2015 • Joined in 2016 • Joined in 2020 20
Slide 25: SWK – Rapidly-Growing Life Science Focused Specialty Finance Company
SWK – Rapidly-Growing Life Science Focused Specialty Finance Company Custom financing solutions for commercial-stage healthcare companies and royalty owners Targeting $5mm to $20mm financings, a niche that is largely ignored by larger market participants Focus is secured financings and royalty monet
Slide 26: Balance Sheet
Balance Sheet $ in 000s Jun-20 Dec-19 Dec-18 Dec-17 Dec-16 ASSETS Cash and cash equivalents $ 17,167 $ 11,158 $ 20,227 $ 30,557 $ 32,182 Interest and accounts receivable, net 2,001 2,554 2,195 1,637 1,054 Marketable investments 1,314 1,802 - 1,856 2,621 Other current assets 2,244 1,087 138 126 240 T
Slide 27: Income Statement
Income Statement $ in 000s, except per share amounts LTM 2Q20 Dec-19 Dec-18 Dec-17 Dec-16 Revenues Finance receivable interest income, including fees $ 29,941 $ 30,117 $ 25,978 $ 26,877 $ 15,747 Pharmaceutical development 919 621 - - - Marketable investments interest income - - - - 92 Income related
Slide 28: Cash Flow Statement
Cash Flow Statement $ in 000s,* LTM 2Q20 Dec-19 Dec-18 Dec-17 Dec-16 Cash flows from operating activities: Consolidated net income $8,125 $23,828 $6,195 $8,251 $32,041 Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated entity -
Slide 29: Reconciliation of Non-GAAP Adjusted Net Income
Reconciliation of Non-GAAP Adjusted Net Income The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non-cash mark-t
Slide 30: Reconciliation of Non-GAAP Specialty Finance Net Income
Reconciliation of Non-GAAP Specialty Finance Net Income The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the specialty finance business for the periods denoted b
Slide 31: Contact Information
Contact Information SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Winston Black: • Jason Rando (Media): ̶ Phone: 972.687.7251 ̶ Phone: 212.375.2665 ̶ Email: wblack@swkhold.com ̶ Email: jrando@tiberend.com • Jody Staggs: • Maureen McEnroe (Investors): ̶ Phone: 972.687
Slide 32: Collaborative Approach to Life Science Financing
Collaborative Approach to Life Science Financing 32